Key result
Warfarin did not show a benefit over antiplatelet or no antithrombotic therapy for the composite of death, MI, or stroke, but was associated with more adverse events.
Why the study?
Does anticoagulation with warfarin reduce the composite outcome of death, myocardial infarction, or stroke in patients with systolic heart failure and normal sinus rhythm?
Does anticoagulation with warfarin reduce the composite outcome of death, myocardial infarction, or stroke in patients with systolic heart failure and normal sinus rhythm?
There is currently no objective evidence to support the routine use of warfarin for anticoagulation in patients with systolic heart failure and normal sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Does not support routine warfarin in systolic HF with sinus rhythm; confirms lack of benefit in Level 1 evidence.
Marino et al. (2008) conducted a review in Systolic heart failure and normal sinus rhythm. Warfarin vs. Antiplatelet therapy or no antithrombotic therapy was evaluated on Composite outcome of death, myocardial infarction, or stroke. Warfarin did not show a benefit over antiplatelet or no antithrombotic therapy for the composite of death, MI, or stroke, but was associated with more adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: